Swedish biotech Oncopeptides has revealed details regarding a formal request from the US Food and Drug Administration to voluntarily withdraw the approval of Pe 25 August 2023
German infectious disease specialist AiCuris Anti-infective Cures has received a milestone payment of around $32.5 million from partner Merck & Co after a new U 23 August 2023
Chinese pharma company Jiangsu Hengrui Pharmaceuticals has granted USA-based ONEBIO exclusive rights to its anti-TSLP monoclonal antibody SHR-1905 in a deal cov 15 August 2023
C4X Discovery (C4XD) has sold its remaining rights to the oral Orexin-1 receptor antagonist, C4X_3256, to fellow British firm Indivior, for $20 million. 1 August 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.